$-15.80
(Market cap
$3 Mln
Recently Viewed
Clear AllMarket cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-64 Mln
ROE
-0.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.9
Debt to Equity
0
Book Value
$1.3
EPS
$-1.9
Face value
--
Shares outstanding
3,229,640
CFO
$-549.90 Mln
EBITDA
$-767.29 Mln
Net Profit
$-528.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
| -83.7 | -88.5 | -82.6 | -89.1 | -78.1 | -67.1 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
| -51.7 | -65.4 | -67.8 | -45.5 | -7.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.9 | 3.0 | 1.2 | -113.0 | -7,739.1 | -90 | -- | 0.0 |
| 22.3 | 185.2 | 0.0 | -124.7 | -494.4 | -52 | -- | 1.0 |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic... stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Read more
President & COO
Dr. Paul Alloway J.D., Ph.D.
President & COO
Dr. Paul Alloway J.D., Ph.D.
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Homology Medicines Inc (FIXX) is $0.89 (NASDAQ) as of 25-Mar-2024 18:27 EDT. Homology Medicines Inc (FIXX) has given a return of -78.07% in the last 3 years.
Since, TTM earnings of Homology Medicines Inc (FIXX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.31
|
0.48
|
|
2022
|
149.96
|
0.41
|
|
2021
|
-2.17
|
1.23
|
|
2020
|
-4.02
|
2.61
|
|
2019
|
-9.55
|
3.62
|
The 52-week high and low of Homology Medicines Inc (FIXX) are Rs -- and Rs -- as of 24-Apr-2026.
Homology Medicines Inc (FIXX) has a market capitalisation of $ 3 Mln as on 05-Apr-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Homology Medicines Inc (FIXX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.